TrialDose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Trial details
- Registry ID
- NCT03760003
- Phase
- Phase 2
Drug research
ABX464 50 mg
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Obefazimod 50 mg
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisNCT03760003 | ABVX | Phase 2 | Completed | 2021-04-01Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |